Combining aspirin and proton pump inhibitors: For whom the warning bell tolls?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 9, 2012, Pages 1051-1055

  Würtz, Morten ^a   Grove, Erik Lerkevang ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Aspirin; Coronary artery disease; Drug interactions; Platelet function testing; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS ESOMEPRAZOLE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; GASTROINTESTINAL AGENT; PROTON PUMP INHIBITOR;

BLEEDING; CARDIOVASCULAR RISK; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; PATIENT COMPLIANCE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; STOMACH PH; UPPER GASTROINTESTINAL BLEEDING;

ASPIRIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 84865309883     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.711318     Document Type: Review

References (19)

1. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321(7270):1183-7
2. Nikolsky E, Stone GW, Kirtane AJ, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009;54(14):1293-302
3. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2010;56(24):2051-66
4. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011;32(15):1854-64
5. Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010;152(1):1-9
6. Tantry US, Kereiakes DJ, Gurbel PA. Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv 2011;4(4):365-80
7. Saini SD, Fendrick AM, Scheiman JM. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention. Aliment Pharmacol Ther 2011;34(2):243-51
8. Niazi M, Andersson T, Naucler E, et al. Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers. Int J Clin Pharmacol Ther 2009;47(9):564-9
9. Niazi M, Andersson T, Naucler E, Naesdal J. Evaluation of bioequivalence between a single-capsule formulation of esomeprazole 40 mg and acetylsalicylic acid 325 mg and the monotherapies given separately in healthy volunteers. Int J Clin Pharmacol Ther 2011;49(2):169-76
10. Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011;342:d2690
11. Inarrea P, Esteva F, Cornudella R, Lanas A. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand J Gastroenterol 2000;35(3):242-6 (Pubitemid 30217174)
12. Adamopoulos AB, Sakizlis GN, Nasothimiou EG, et al. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study. J Cardiovasc Pharmacol 2009;54(2):163-8
13. Wurtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 2010;96(5):368-71
14. Study to evaluate the interaction between Aspirin and Nexium. Clinicaltrials.gov registration: NCT01199328. Available from: http://clinicaltrials.gov/ct2/results? term=NCT01199328 [Accessed 21 June 2012]
15. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363(20):1909-17
16. Bardou M, Barkun AN, Hamza S, et al. Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients. Expert Opin Drug Metab Toxicol 2012;8(9):1199-08
17. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376(9748):1233-43
18. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50, 279 patients at risk for coronary artery disease. Eur Heart J 2006;27(22):2667-74 (Pubitemid 44729867)
19. Food interaction study to asses the effect of food on the pharmakokinetics of esomeprazole 20 mg/acetylsalicylic acid 81 mg. Clinicaltrials.gov registration: NCT01163630. Available from: http://clinicaltrials.gov/ct2/results?term= NCT01163630 [Accessed 21 June 2012]